Prostaglandin E2 systemic production in patients with asthma with and without aspirin hypersensitivity

Mastalerz, L.; Sanak, M.; Gawlewicz-Mroczka, A.; Gielicz, A.; Cmiel, A.; Szczeklik, A.
January 2008
Thorax;Jan2008, Vol. 63 Issue 1, p27
Academic Journal
Background: A special regulatory role for prostaglandin E2 has been postulated in aspirin-induced asthma. A study was undertaken to investigate the effects of aspirin on the systemic production of prostaglandin E2 and cysteinyl leucotrienes in patients with asthma. Methods: The urinary concentrations were determined of two main prostaglandin [2 metabolites (13,14-dihydro-15keto-PGE2 using a commercial enzyme immunoassay and 9,15-dioxo-11αhydroxy-2,3,4,5-tetranor-prostane-1,20-dioic acid by gas chromatography/mass spectrometry) and leucotriene E4 using an immunoassay. Determinations were performed at baseline and following oral aspirin and celecoxib challenges in two well-defined asthma phenotypes: aspirin-sensitive and aspirin-tolerant patients. Results: Aspirin precipitated bronchial reactions in all aspirin-sensitive patients but in none of the aspirin-tolerant patients. Celecoxib 400 mg was well tolerated by all patients except for one with aspirin-induced asthma. At baseline, the mean levels of prostaglandin E2 metabolites did not differ between the groups. Following different aspirin provocation doses, the mean levels of the two main prostaglandin E2 metabolites were decreased in the aspirin-tolerant group but remained unchanged in the aspirin-sensitive group. The dose of aspirin had no effect on the magnitude of the response on the prostaglandin [2 metabolites and its duration. In both groups, urinary prostaglandin E2 metabolites decreased following celecoxib challenge. No correlation was found between prostaglandin E2 metabolites and leucotriene E4. Conclusions: Aspirin-precipitated asthmatic attacks are not associated with changes in the systemic production of prostaglandin [2. In contrast, the systemic production of prostaglandin [2 becomes depressed by aspirin in non-sensitive patients. This different response might indicate COX-1-dependent prostaglandin E2 control of inflammatory cells in aspirin-induced asthma. Thus, PGE2 is released during the clinical reactions to aspirin through an alternative COX-2 pathway. The clinical implications of this finding are in line with current observations of good tolerance of the selective COX-2 inhibitors in aspirin-sensitive patients.


Related Articles

  • An alternative anti-inflammatory drug can be found to treat the majority of patients with asthma and aspirin hypersensitivity.  // Drugs & Therapy Perspectives;Oct2007, Vol. 23 Issue 10, p25 

    Approximately 5–20% of patients with chronic asthma have aspirin hypersensitivity and develop cross-reactions to other NSAIDs that have strong cyclo-oxygenase-1 inhibitory activity. After careful consideration, an appropriate alternative can be found to treat the majority of...

  • Selective cyclooxygenase-2 inhibitor cross-reactivity in aspirin-exacerbated respiratory disease. Umemoto, Junichi; Tsurikisawa, Naomi; Nogi, Shinichi; Iwata, Kanako; Oshikata, Chiyako; Tatsuno, Sayaka; Tanimoto, Hidenori; Sekiya, Kiyoshi; Tsuburai, Takahiro; Mitomi, Hiroyuki; Akiyama, Kazuo // Allergy & Asthma Proceedings;May/Jun2011, Vol. 32 Issue 3, p259 

    Aspirin-induced asthma (AIA) is a severe and difficult-to-treat allergic disease in which acute asthma attacks are induced by nonsteroidal anti-inflammatory drugs. Patients with AIA rarely experience asthma attacks when taking celecoxib, a specific inhibitor of cyclooxygenase (COX) 2. A...

  • Functional studies of genes involved in pathogenesis of aspirin-induced asthma. Kacprzak, Dorota; Pawliczak, Rafał // Advances in Dermatology & Allergology / Postepy Dermatologii i A;2012, Vol. 29 Issue 3, p161 

    About one fifth of asthmatics have aspirin intolerance. There are several theories explaining pathogenesis of aspirin-induced asthma (AIA). According to the cyclooxygenase theory, aspirin inhibits cyclooxygenase enzymes leading to prostaglandins (PGs) biosynthesis inhibition. In turn, deficiency...

  • Tolerance and rebound with zafirlukast in patients with persistent asthma. Reid, David W.; Misso, Neil L.; Aggarwal, Shashi; Thompson, Philip J.; Johns, David P.; Walters, E. Haydn // Journal of Negative Results in Biomedicine;2008, Vol. 7, Special section p1 

    Background: The potential for tolerance to develop to zafirlukast, a cysteinyl leukotriene (CysLT) receptor antagonist (LRA) in persistent asthma, has not been specifically examined. Objective: To look for any evidence of tolerance and potential for short-term clinical worsening on LRA...

  • Impact of aspirin on the gastrointestinal-sparing effects of cyclooxygenase-2 inhibitors. Nathan, Joseph P.; Castellanos, Julia T.; Rosenberg, Jack M.; Cicero, Lorraine A. // American Journal of Health-System Pharmacy;2/15/2003, Vol. 60 Issue 4, p392 

    Discusses the effects of aspirin on the gastrointestinal (GI)-sparing effects of cyclooxygenase (COX)-2 inhibitors. Aspirin-induced GI complications; Pathogenesis of GI effects of COX-2 inhibitors; GI safety of COX-2 inhibitors; Combination therapy with aspirin and COX-2 inhibitors.

  • Effects of acetylsalicylic acid and celecoxib on the N-nitrosodiethylamine induced carcinogenesis in rat liver and esophagus. L. Bolieva; F. Dzhioev; S. Kakabadze // Bulletin of Experimental Biology & Medicine;Jan2007, Vol. 143 Issue 1, p87 

    Abstract  The effects of nonsteroid antiinflammatory drugs (acetylsalicylic acid and celecoxib) on N-nitrosodiethylamine-induced carcinogenesis in the liver and esophagus were studied in rats. The inhibitory effect of celecoxib on carcinogenesis was more pronounced (in comparison with...

  • Aspirin and cancer: has aspirin been overlooked as an adjuvant therapy? Langley, R E; Burdett, S; Tierney, J F; Cafferty, F; Parmar, M K B; Venning, G // British Journal of Cancer;10/11/2011, Vol. 105 Issue 8, p1107 

    Aspirin inhibits the enzyme cyclooxygenase (Cox), and there is a significant body of epidemiological evidence demonstrating that regular aspirin use is associated with a decreased incidence of developing cancer. Interest focussed on selective Cox-2 inhibitors both as cancer prevention agents and...

  • Radiation-enhancement of MDA-MB-231 breast cancer cell invasion prevented by a cyclooxygenase-2 inhibitor. Paquette, B.; Therriault, H.; Desmarais, G.; Wagner, R.; Royer, R.; Bujold, R. // British Journal of Cancer;8/9/2011, Vol. 105 Issue 4, p534 

    Background: Recent evidences support that radiation can promote the invasion of cancer cells. As interactions between cancer cells and surrounding stromal cells can have an important role in tumour progression, we determined whether an irradiation to fibroblasts can enhance the...

  • Minerva.  // BMJ: British Medical Journal (International Edition);4/27/2002, Vol. 324 Issue 7344, p1046 

    Offers medical information compiled from various sources. Potential explanation for why people who switch from daily aspirin to one of the new COX-2 inhibitors sometimes experience cardiac complications; Findings regarding the benefits of vaccinating children with asthma; Legal issues raised by...


Read the Article


Sign out of this library

Other Topics